Date updated:01-05-2007
One hundred years ago, Dr. Alois Alzheimer identified the ailment that bears his name. Scientists are now decoding the disease and testing drugs that could delay and maybe even cure Alzheimer's. Here are the public companies who are beind these drugs designed to treat, delay or prevent Alzheimer's.
According to a recent BusinessWeek article, "there are currently 4.5 million Alzheimer's patients in the U.S., and the direct and indirect costs of caring for them total more than $100 billion a year, making Alzheimer's the third most expensive illness after heart disease and cancer. Yet the federal government budgeted only $645 million for Alzheimer's research for 2007, $7 million less than the prior year. In contrast, $2.6 billion was allocated for research into HIV/AIDS, which afflicts one million Americans."

-
NRMX
N/a - $2.00
- 0.00
- $2.00
The drug Alzhemed is being produced by Neurochem. It prevents the accumulation of amyloid, a toxic protein that destroys brain cells in Alzheimer's victims. It's in Phase 3 late stage testing. The data on Alzhemed have been promising but scant. In a 2002 study it stabilized the disease in nine patients over six months, but the small sample left plenty of specialists skeptical. A clinical trial of the drug will wrap up in January, with results expected in the spring.

-
MYGN
Myriad Genetics - $37.70
- +2.20%
- $36.67
The drug Flurizan is being produced by Myriad Genetics. It inhibits the production of amyloid. It's in Phase 3 of testing with results expected next summer.

-
NHPI.OB
Neuro-hitech Inc - $0.10
- 0.00%
- $0.10
The drug Huperzine is being produced by Neuro-Hitech. It strengthens memory formation and may protect brain cells from damage caused by Alzheimer's. It's in Phase 2 mid-stage testing.

-
MEMY
Memory Pharmaceut - $0.606
- 0.00%
- $0.605
The drug MEM1003 is being produced by Memory Pharmaceuticals. It evens out the irregularities in brain levels of calcium - one of the first manifestations of Alzheimer's. It's in Phase 2 of testing.

-
WYE
Wyeth - $45.00
- 0.00%
- $44.91
The drug AAB-001 is being produced by Wyeth and Elan. It's a monoclonal antibody that seeks out and removes amyloid in the brain. It's in Phase 2 of testing.

-
LLY
Lilly (eli) & Co. - $35.05
- 0.00%
- $34.50
The drug LY450139 is being produced by Eli Lilly. It blocks an enzyme that snips off amyloid fragments, thus reducing the production of amyloid. It's in Phase 2 of testing.

-
ELN
Elan Corp Plc - $7.37
- 0.00%
- $7.68
The drug ACC-101 is being produced by Elan and Wyeth. The vaccine prompts the body's immune system to attack and remove amyloid in the brain. It's in Phase 1 (early safety tests)

-
DNA
N/a - $80.43
- 0.00
- $80.43
Nearly 60 drugs designed to modify the disease are in clinical trials. One is from AC Immune of Switzerland who recently struck a deal with biotech power player Genentech Inc. (DNA ). While known for its cancer treatments, Genentech just announced plans to invest $300 million for the rights to AC Immune's drug.
- Alzheimer's Cure Index's Blog
- No Blogs Found
- Top Professional Portfolios
- 1. Navellier & Associ...
- 2. Highbridge Statistical...
- 3. Joel Greenblatt
- 4. Amana Trust Growth - A...
- 5. Fidelity International...
- show all
- Top Do-It-Yourself Portfolios
- » agtest1
- » Joy
- » tsamanuli Portfolio 1
- » brueckenc Portfolio 1
- » HMH1
- show all
- Most Viewed Portfolios
- » Warren Buffett
- » George Soros
- » T. Boone Pickens - BP Cap...
- » Carl Icahn
- » Renaissance Technologies
- show all
By Stockpickr Staff Posted on July 2, 2009 Developments in the stem cell world are starting to get very interesting. On Tuesday, General Electric (GE) signed an exc...
By Rebecca Corvino Posted on July 2, 2009 Every day, Stockpickr members are creating and sharing stock ideas with each other through various platforms. If you're not al...
By Rebecca Corvino Posted at 12:30 p.m. EDT on July 2, 2009 Making Thursday's headlines and sending stocks lower were reports that June saw the loss of 467,000 more job...
By Stockpickr Staff Posted on July 2, 2009 Some investors assume that at this time of year, it's the summer doldrums for the stock market. After all, as the saying goe...
A. commodities also down across the board.
i think guidance will be the real market
mover, cause i think we only have q3
left for peoples patience to run out.
mike
A. The only one I own : SLX,
too hard pick a winner out all of them
Here is the stock list of some of the largest % losers from July 1, 2009. more
Here are some of the largest % gainers from July 1, 2009. more
Analyst Downgrades for July 1, 2009. Read more here. more






Comments not available